Pharmaceuticals Inc. at 844-627-4687 or FDA at 1-800-FDA-1088 Advise the patient to read the FDA-approved patient labeling (Medication Guide and ...
888-4231 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. The following important adverse reactions are described elsewhere in the labeling:.
at 1-844-IMMUNO1 (1-844-466-8661) or FDA at 1-800-FDA-1088 or serious adverse reactions are discussed in greater detail in other sections of the label:.
See FDA-approved patient labeling (Medication Guide). Advise patients of the following: • They should not discontinue ELIQUIS without talking to their
Advise the patient to read the FDA-approved patient labeling (Medication Guide). Serious Infections. Inform patients that XELJANZ/XELJANZ XR may lower the
See 17 for PATIENT COUNSELING INFORMATION and FDA- approved patient labeling. Revised: 7/2018. FULL PRESCRIBING INFORMATION: CONTENTS*.
in another section of the labeling: Anemia and neutropenia [see Warnings and with chronic hepatitis C in one Phase 2 open-label trial and two Phase 3
Assessment of HER2 protein overexpression and HER2 gene amplification in metastatic gastric cancer should be performed using FDA-approved tests specifically for
Oct 2 2021 FDA-approved patient labeling. Revised: 10/2021. FULL PRESCRIBING INFORMATION: CONTENTS*. 1. INDICATIONS AND USAGE. 1.1 Early Breast Cancer.
018281s048lbl.pdf